Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Surufatinib Plus Standard Chemotherapy Versus Surufatinib Monotherapy in Patients With Pulmonary Neuroendocrine Tumors: a Randomized, Controlled, Open-label Study

NCT07357623 is registered in ClinicalTrials.gov with Shanghai Chest Hospital as lead sponsor.

NCT NCT07357623
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07357623 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Surufatinib Plus Standard Chemotherapy Versus Surufatinib Monotherapy in Patients With Pulmonary Neuroendocrine Tumors: a Randomized, Controlled, Open-label Study
Lead sponsor
Shanghai Chest Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
September 22, 2025
Completion date
September 1, 2028
Enrollment
96 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary neuroendocrine tumor